OakChart

Enanta Pharmaceuticals Inc

ENTAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:13 PM ET

11.60+0.38 (3.39%)
2026-11-11 20:15 CET
Market cap
326.79 USD m
Revenue, TTM
65.26 USD m
Net income, TTM
-63.23 USD m
Free cash flow, TTM
-36.94 USD m
EPS diluted, TTM
-2.41
P/E
-
Compare

Price

ENTA against its 20, 50 and 200-day averages
2050200beatmiss
10.0012.0014.0016.00467K935KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENTAclose 11.6020-day 11.2350-day 12.07200-day 13.1211.6052w low

32.4% under the 52-week high of 17.15 on 29 Dec 2025. 52-week low 10.05 on 5 Nov 2026. Last 15 sessions, 23.3% high to low

Profile

ENTA
52-week range, 22% of the way up
10.0517.15

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

IndexRUT
Employees120
IPOMar 21, 2013
Beta0.75
ATR, 14d0.72
Rel volume0.54
Short float6.69%
Insider own4.74%
Inst own93.01%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap337.86M
Enterprise Value330.39M
Income-63.23M
Sales65.26M
Book/sh3.47
Cash/sh6.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees120
IPOMar 21, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S5.18
P/B3.34
P/C1.78
P/FCF-
EV/EBITDA-
EV/Sales5.06
Quick Ratio3.76
Current Ratio3.76
Debt/Eq1.80
LT Debt/Eq1.40
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.41
EPS next Y-2.20
EPS next Q-0.72
EPS this Y40.29%
EPS next Y4.13%
EPS next 5Y11.43%
EPS past 3/5Y13.40% -16.17%
Sales past 3/5Y-8.82% -11.81%
EPS Y/Y TTM44.24%
Sales Y/Y TTM0.70%
EPS Q/Q21.50%
Sales Q/Q-21.60%
EarningsAug 10 AMC
EPS/Sales Surpr.-31.50% -14.34%

Ownership

Insider Own4.74%
Insider Trans0.00%
Inst Own93.01%
Inst Trans2.31%
ROA-21.15%
ROE-70.12%
ROIC-26.08%
Gross Margin92.48%
Oper. Margin-89.99%
Profit Margin-96.89%
SMA203.28%
SMA50-3.88%
SMA200-11.55%
Trades-

Technical

Shs Outstand29.12M
Shs Float27.75M
Short Float6.69%
Short Ratio7.13
Short Interest1.86M
52W High17.15 -32.36%
52W Low10.05 15.42%
Volatility8.64% 6.67%
ATR (14)0.72
RSI (14)51.50
Beta0.75
Rel Volume0.54
Avg Volume260.36K
Volume103,852

Performance

Perf Week8.92%
Perf Month0.69%
Perf Quarter-13.69%
Perf Half Y-17.32%
Perf YTD-26.44%
Perf Year-3.65%
Perf 3Y40.44%
Perf 5Y-87.25%
Perf 10Y-58.78%
Recom1.17
Target Price21.83
Prev Close11.22
Price11.60
Change %3.39%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Mar 26, 2026InitiatedRRodman & RenshawBuy$20+72.4%
Nov 14, 2025InitiatedJJP MorganOverweight
Oct 01, 2025UpgradeJJefferiesHold → Buy$20+72.4%
Jul 28, 2025ResumedHH.C. WainwrightBuy$20+72.4%
Aug 09, 2023DowngradeJJP MorganNeutral → Underweight$14+20.7%
Aug 08, 2023DowngradeJJefferiesBuy → Hold$49 → $18+55.2%
Dec 09, 2022InitiatedHH.C. WainwrightBuy$56+382.8%
Jul 06, 2022UpgradeEEvercore ISIIn-line → Outperform$62+434.5%
Jun 01, 2022UpgradeEEvercore ISIUnderperform → In-line$39+236.2%
Oct 07, 2021InitiatedJJefferiesBuy$95+719.0%

Peers

Mkt cap
TickerCompanyMkt cap
AVIRAtea Pharmaceuticals Inc339.69M
CLDXCelldex Therapeutics Inc2.39B
ASMBAssembly Biosciences Inc456.77M
KYMRKymera Therapeutics Inc11.56B
VIRVir Biotechnology Inc2.25B
IVVDInvivyd Inc173.26M
JSPRJasper Therapeutics Inc16.36M
COCPCocrystal Pharma Inc19.84M
ABUSArbutus Biopharma Corp764.68M
ALGSAligos Therapeutics Inc15.36M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Capps Kathleen S.See RemarksDec 05 '25Sale14.233234,5968,377Dec 05 06:53 PM
Trout Harry R. IIISee RemarksDec 05 '25Sale14.235427,71316,348Dec 05 06:47 PM
Rottinghaus Scott T.Chief Medical OfficerDec 05 '25Sale14.2379811,35621,792Dec 05 06:46 PM
Luu BrendanChief Business OfficerDec 05 '25Sale14.231,39419,83738,329Dec 05 06:45 PM
Kieffer Tara LynnChief Product Strategy OfficerDec 05 '25Sale14.232,10629,96830,620Dec 05 06:44 PM
Or Yat SunChief Scientific OfficerDec 05 '25Sale14.232,39034,010371,392Dec 05 06:43 PM
Luly Jay R.President and CEODec 05 '25Sale14.234,74367,493858,026Dec 05 06:41 PM
Luly Jay R.OfficerDec 05 '25Proposed Sale14.244,74367,540Dec 05 06:38 PM
Capps Kathleen S.See RemarksDec 02 '25Sale13.962072,8908,700Dec 03 05:09 PM
Trout Harry R. IIISee RemarksDec 02 '25Sale13.963805,30516,890Dec 03 05:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-10-0.670-0.510-0.67014.3616.765
2026Q22026-05-11-0.450-0.487-0.45117.1617.035
2026Q12026-02-09-0.420-0.768-0.41518.6215.913
2025Q42025-11-17-0.870-1.021-0.87515.1315.987
2025Q32025-08-11-0.850-0.900-0.85418.3115.545
2025Q22025-05-12-1.060-1.147-1.06014.9315.956
2025Q12025-02-10-1.050-1.353-1.05016.9617.254
2024Q42024-11-25-1.360-1.161-1.36014.6117.938
2024Q32024-08-05-1.070-1.433-1.07017.9717.448
2024Q22024-05-06-1.470-1.336-1.47217.0516.098
2024Q12024-02-07-1.580-1.226-1.58418.0021.955
2023Q42023-11-20-1.330-2.124-1.33518.9317.497
2023Q32023-08-07-1.860-2.249-1.85618.8918.197
2023Q22023-05-08-1.790-1.963-1.79017.8019.049
2023Q12023-02-07-1.390-1.573-1.39323.5923.557
2022Q42022-11-21-1.270-1.252-1.27020.3223.139

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY2.2102.3192.212205.2209.85
2020FY-1.810-1.238-1.814122.47124.41
2021FY-3.920-3.859-3.91697.0799.90
2022FY-5.910-5.861-5.91086.1689.04
2023FY-6.380-7.232-6.38279.2077.13
2024FY-5.480-5.280-5.48567.6471.21
2025FY-3.840-3.773-3.84065.3266.16
2026FY--2.293--64.75
2027FY--2.198--60.42
2028FY--2.668--58.85
2029FY--3.050--60.54
2030FY--2.715--102.33

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0140014.6213.7016.00
2026Q4S2026-10-2540114.6213.7016.00
2026Q4S2026-09-2540314.6213.7016.00
2026Q4S2026-08-1850315.7013.7020.00
2026Q4S2026-08-1150216.1813.7020.00
2026Q4S2026-08-0151016.6413.7020.00
2026Q4S2026-07-2652016.6413.7020.00
2026Q4S2026-06-2952116.6413.7020.00
2026Q4S2026-06-2263116.6513.7020.00
2026Q4S2026-06-1763116.5313.7020.00
2026Q4S2026-05-1853115.8413.7016.70
2026Q4S2026-05-1652115.7413.7016.70
2026Q4S2026-05-1253115.7413.7016.70
2026Q4S2026-05-0651015.9813.7019.00

Estimate history

EPS, annual0.913.4852.212-1.814-3.916-5.91-6.382-5.485-3.838-2.4111
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.07-1.36-1.05-1.06-0.854-0.875-0.415-0.451-0.67
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual102.814206.625205.197122.47397.07486.1679.20467.63565.32465.26
Period201720182019202020212022202320242025TTM
Sales, quarterly17.97114.60716.95914.92618.31415.12518.61517.15914.359
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.1219.39519.70320.07720.23820.79121.05921.19421.38729.12
Period201720182019202020212022202320242025MRQ
Shares, quarterly21.18221.19421.33321.37721.37821.38729.01929.06129.12
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue65.2665.3267.6479.2086.1697.07122.47205.20206.62
Cost of Goods Sold Incl. D&A4.914.592.342.372.97----
Gross Profit60.3560.7465.3076.8383.19----
Selling, General and Administrative Excl. Other119.08146.09186.99214.04207.03203.31160.47165.20115.78
Research and Development86.24106.74131.48163.52164.52174.11136.76142.2194.86
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-58.73-85.35-121.69-137.21-123.84-109.57-41.6436.7488.33
Interest Expense12.927.6810.945.15-----
Unusual Expense0.00-0.04-0.070.00-0.080.03-0.150.000.06
Net Income Before Taxes-63.13-83.55-117.79-131.00-122.19-107.58-35.0245.5693.12
Income Taxes0.10-1.66-1.742.82-0.43-28.581.15-0.8321.16
Consolidated Net Income-63.23-81.89-116.05-133.82-121.75-79.00-36.1746.3871.96
Net Income From Continuing Operations-63.23-81.89-116.05-133.82-121.75-79.00-36.1746.3871.96
Net Income-63.23-81.89-116.05-133.82-121.75-79.00-36.1746.3871.96
EPS (Recurring)-2.17-3.84-5.49-6.38-5.91-3.92-1.822.213.49
EPS (Basic, Before Extraordinaries)-2.41-3.84-5.49-6.38-5.91-3.92-1.812.373.74
EPS (Diluted)-2.41-3.84-5.49-6.38-5.91-3.92-1.812.213.48
EBITDA-53.82-80.76-119.36-134.84-120.87-106.24-37.9940.0090.85
Non-Operating Income (Expense)8.519.4414.7711.361.572.026.478.824.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.0714.6721.1722.2921.3115.3214.2914.0312.52
Price To Earnings Ratio-------27.0621.21
Price To Sales Ratio6.503.913.242.9612.4011.807.456.148.54
Gross Margin92.4892.9896.5597.0196.55----
Operating Margin-89.99-130.65-179.92-173.23-143.74-112.88-34.0017.9042.75
Net Margin-96.89-125.36-171.58-168.95-141.31-81.38-29.5322.6034.82
Shares Outstanding29.1221.3921.1921.0620.7920.2420.0819.7019.39
Market Capitalization326.79326.79219.51235.191,075.001,148.40918.901,182.491,656.04

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue14.3617.1618.6115.1218.3114.9316.9614.61
Cost of Goods Sold Incl. D&A1.191.211.231.281.211.200.890.48
Gross Profit13.1715.9517.3913.8417.1013.7216.0714.13
Selling, General and Administrative Excl. Other30.4127.8028.6432.2336.0038.2539.6143.98
Research and Development22.1319.4420.8623.8127.2128.0727.6630.78
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.24-11.85-11.25-18.39-18.89-24.53-23.54-29.85
Interest Expense4.133.323.082.391.621.711.962.58
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-19.46-13.08-11.91-18.67-18.23-23.95-22.71-29.19
Income Taxes0.040.010.020.030.03-1.30-0.42-0.36
Consolidated Net Income-19.50-13.09-11.94-18.70-18.25-22.64-22.29-28.82
Net Income From Continuing Operations-19.50-13.09-11.94-18.70-18.25-22.64-22.29-28.82
Net Income-19.50-13.09-11.94-18.70-18.25-22.64-22.29-28.82
EPS (Recurring)-0.67-0.45-0.42-0.87-0.85-1.06-1.05-1.36
EPS (Basic, Before Extraordinaries)-0.67-0.45-0.42-0.87-0.85-1.06-1.05-1.36
EPS (Diluted)-0.67-0.45-0.42-0.87-0.85-1.06-1.05-1.36
EBITDA-16.05-10.64-10.02-17.10-17.68-23.32-22.65-29.38
Non-Operating Income (Expense)1.902.082.422.102.292.292.803.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.912.963.013.193.303.704.486.10
Price To Sales Ratio6.505.306.773.922.491.831.833.25
Gross Margin91.7592.9593.3991.5193.3991.9494.7696.72
Operating Margin-120.04-69.07-60.45-121.56-103.16-164.32-138.82-204.38
Net Margin-135.81-76.29-64.13-123.64-99.68-151.71-131.43-197.32
Shares Outstanding29.1229.0629.0221.3921.3821.3821.3321.19
Market Capitalization326.79366.51455.16255.89161.61117.76121.87219.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments188.86248.79369.91249.23244.00386.65335.24308.73223.67
Short Term Receivables6.8838.6539.6249.0460.8323.4951.3167.2010.61
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets8.5912.4113.2613.4514.1926.7015.304.453.54
Total Current Assets204.34299.85422.79311.71319.02436.84401.85380.39237.82
Net Property, Plant & Equipment72.9473.3534.7129.7510.6515.6210.938.378.05
Total Investments and Advances3.363.363.9733.25109.0233.2465.6217.0070.65
Intangible Assets0.00-------0.00
Deferred Tax Assets11.9814.157.565.182.075.0012.559.3211.34
Other Assets0.090.090.800.700.090.090.090.090.00
Total Assets292.72390.80469.84380.59440.86490.79491.04415.17327.85
Short Term Debt Incl. Current Port. of LT Debt33.8635.9940.352.894.204.260.000.000.08
Accounts Payable1.958.004.106.009.545.746.694.753.71
Income Tax Payable------0.001.399.30
Other Current Liabilities12.7513.5518.3420.9422.4314.1615.929.897.89
Total Current Liabilities48.5557.5362.7929.8336.1724.1622.6116.0220.98
Long Term Debt167.20190.07182.0923.802.635.321.831.921.14
Provision for Risks Charges0.000.000.000.000.561.082.002.011.35
Deferred Tax Liabilities11.9814.157.565.182.074.661.210.941.21
Other Liabilities0.260.230.660.450.000.000.900.591.48
Total Liabilities228.00261.99253.1059.2641.4335.2128.5521.4926.18
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity64.72128.81216.74321.33399.43455.58462.49393.68301.68
Total Shareholders Equity64.72128.81216.74321.33399.43455.58462.49393.68301.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity64.72128.81216.74321.33399.43455.58462.49393.68301.68
Total Liabilities & Stockholders Equity292.72390.80469.84380.59440.86490.79491.04415.17327.85
Book Value Per Share3.036.0810.2915.4619.7422.6923.4720.3015.78
Tangible Book Value Per Share3.036.0810.2915.4619.7422.6923.4720.3015.78
Full-Time Employees12013114516015514113211389
Price to Book Ratio3.231.470.993.362.882.022.564.583.42
Return on Assets-23.96-26.97-31.47-29.64-16.96-7.3710.2419.375.81
Return on Equity-84.63-67.17-49.74-33.79-18.48-7.8810.8320.706.20
Return on Invested Capital-35.31-36.39-33.55-35.28-19.65-7.859.9918.195.85
Quick Ratio4.215.216.7310.458.8218.0817.7723.7411.33
Current Ratio4.215.216.7310.458.8218.0817.7723.7411.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-63.23-81.89-116.05-133.82-121.75-79.00-36.1746.3871.96
Depreciation4.914.592.342.372.973.333.643.262.52
Other Funds (Non Cash)18.0318.1227.8220.2727.2119.0116.1013.4214.68
Funds from Operations-40.29-59.18-85.89-111.18-91.57-56.31-5.8159.9391.01
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.9739.917.138.026.79-13.6912.9011.49-61.79
Income Taxes Payable-----0.000.00-1.39-7.91
Cash from Operating Activities-35.32-19.27-78.76-103.15-84.78-70.007.0971.4229.22
Capital Expenditures-1.62-12.90-17.95-9.06-2.12-0.75-1.45-5.42-2.98
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-17.4353.2476.18-44.5257.0237.7421.27-81.25-32.42
Purchase of Investments-284.70-209.63-307.28-373.39-171.45-307.35-338.55-549.31-293.10
Sale Or Maturity of Investments267.27262.87383.46328.87228.47345.09359.83468.06260.68
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-19.0540.3558.23-53.5854.9036.9919.83-86.66-35.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock70.680.140.152.2121.263.6110.486.856.24
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock70.680.140.152.2121.263.6110.486.856.24
Proceedsfrom Stock Options69.950.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-26.49-26.49-27.48199.680.000.000.00-0.09-0.08
Change in Long Term Debt-26.49-26.49-27.48199.680.000.000.00-0.09-0.08
Issuance of Long Term Debt0.000.000.00199.680.000.000.000.000.00
Reduction of Long Term Debt-26.49-26.49-27.480.000.000.000.00-0.09-0.08
Net Financing Active Other Cash Flow-1.22-0.28-0.29-3.76-1.23-0.53-1.50-4.19-1.76
Other Financing Activities Uses-1.22-0.28-0.29-3.76-1.23-0.53-1.50-4.19-1.76
Cash from Financing Activities42.98-26.62-27.63198.1320.033.088.982.574.41
Net Change in Cash-11.39-5.54-48.1641.39-9.85-29.9335.90-12.67-1.77
Free Cash Flow-36.94-32.17-96.71-112.21-86.91-70.755.6466.0026.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------161.7719.0967.26
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.3410.61-3.141.86

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments189.51163.77185.85188.86204.11193.38
Short Term Receivables6.537.838.496.888.3640.63
Inventories0.000.000.000.000.000.00
Other Current Assets7.586.814.348.5910.248.86
Total Current Assets203.62178.41198.68204.34222.71242.86
Net Property, Plant & Equipment67.7969.5571.3172.9474.8776.67
Total Investments and Advances25.3566.6059.413.363.363.36
Intangible Assets---0.00--
Deferred Tax Assets---11.98--
Other Assets0.110.140.090.090.090.10
Total Assets296.87314.70329.50292.72301.03322.99
Short Term Debt Incl. Current Port. of LT Debt40.6935.2235.2733.8630.1532.88
Accounts Payable3.294.361.891.953.554.76
Other Current Liabilities10.186.867.5812.7510.858.31
Total Current Liabilities54.1746.4444.7348.5544.5545.95
Long Term Debt141.35151.40157.91167.20176.95183.26
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---11.98--
Other Liabilities0.290.280.270.260.250.24
Total Liabilities195.80198.12202.91228.00221.75229.46
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity101.07116.59126.5964.7279.2893.54
Total Shareholders Equity101.07116.59126.5964.7279.2893.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity101.07116.59126.5964.7279.2893.54
Total Liabilities & Stockholders Equity296.87314.70329.50292.72301.03322.99
Book Value Per Share3.474.014.363.033.714.38
Tangible Book Value Per Share3.474.014.363.033.714.38
Full-Time Employees---120--
Price to Book Ratio3.232.905.213.231.731.05
Return on Assets-21.15-19.44-21.10-23.96-26.29-26.18
Return on Equity-70.12-59.00-60.01-84.63-80.64-74.26
Return on Invested Capital-8.04-4.88-4.20-8.06-7.12-8.18
Quick Ratio3.763.844.444.215.005.29
Current Ratio3.763.844.444.215.005.29

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-19.50-13.09-11.94-18.70-18.25-22.64
Depreciation1.191.211.231.281.211.20
Other Funds (Non Cash)5.834.781.895.542.255.84
Funds from Operations-12.49-7.11-8.82-11.87-14.80-15.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.52-0.05-2.885.3832.302.11
Cash from Operating Activities-9.97-7.16-11.70-6.4917.51-13.49
Capital Expenditures-0.01-0.01-0.14-1.46-0.15-2.54
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments14.0111.96-47.163.75-26.33-1.83
Purchase of Investments-25.51-41.95-148.62-68.62-85.99-55.02
Sale Or Maturity of Investments39.5253.91101.4772.3859.6653.19
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities14.0111.94-47.302.30-26.48-4.37
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.490.0570.090.050.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.490.0570.090.050.000.00
Proceedsfrom Stock Options0.000.0069.950.000.000.00
Issuance or Reduction of Debt, Net0.000.000.00-26.490.000.00
Change in Long Term Debt0.000.000.00-26.490.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-26.490.000.00
Net Financing Active Other Cash Flow-6.03-7.34-5.9518.11-6.42-6.89
Other Financing Activities Uses-6.03-7.34-5.9518.11-6.42-6.89
Cash from Financing Activities-5.54-7.2964.14-8.32-6.42-6.89
Net Change in Cash-1.51-2.515.14-12.51-15.40-24.74
Free Cash Flow-9.98-7.17-11.84-7.9517.35-16.03

Revenue breakdown

Royalty2024: 67.64M 2025: 65.32M
United States2024: 67.64M 2025: 65.32M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.69%1.9M27.8M246.86K
2026-10-158.16%2.3M27.8M229.83K
2026-09-309.20%2.6M27.8M218.03K
2026-09-159.37%2.6M27.8M223.70K
2026-08-319.46%2.6M27.7M214.76K
2026-08-149.69%2.7M27.7M206.10K
2026-07-319.37%2.6M27.6M215.30K
2026-07-158.84%2.4M27.6M210.68K
2026-06-309.36%2.6M27.6M197.69K
2026-06-158.79%2.4M27.6M168.55K
2026-05-298.24%2.3M27.6M168.56K
2026-05-157.98%2.2M27.6M167.65K
2026-04-307.83%2.2M27.5M159.70K
2026-04-157.63%2.1M27.5M178.11K
2026-03-317.75%2.1M27.5M202.48K
2026-03-137.86%2.2M27.5M266.33K
2026-02-277.94%2.2M27.5M280.19K
2026-02-138.27%2.3M27.5M300.72K
2026-01-308.19%2.3M27.6M318.86K
2026-01-158.22%2.3M27.4M373.19K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.507.1010.900.0019.1330.000.000.966-0.0620.001
call5.004.608.400.009.7940.000.000.907-0.1140.003
call7.502.105.900.006.1940.000.000.879-0.0610.004
call10.000.053.501.004.0024.000.000.720-0.0800.006
call12.500.000.700.271.4503791.000.447-0.0710.007
call15.000.002.200.752.34328.000.000.307-0.0840.006
call17.500.002.150.003.1820.000.000.260-0.1000.006
call20.000.002.150.003.6790.000.000.238-0.1100.005
call22.500.002.150.004.0890.000.000.223-0.1180.005
call25.000.002.150.004.4410.000.000.212-0.1250.005
put2.500.002.150.0011.7080.000.00-0.041-0.1000.002
put5.000.002.150.004.9680.000.00-0.071-0.0680.002
put7.500.002.150.002.9710.000.00-0.121-0.0610.004
put10.000.000.900.201.48929.0051.00-0.228-0.0450.005
put12.500.003.401.553.95430.000.00-0.559-0.0680.007
put15.001.655.600.004.4940.000.00-0.695-0.0830.006
put17.504.108.100.005.3630.000.00-0.737-0.0980.006
put20.006.6010.600.005.7750.000.00-0.762-0.1090.006
put22.509.1013.000.006.1040.000.00-0.777-0.1170.005
put25.0011.6015.400.006.5000.000.00-0.789-0.1230.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-298-KCurrent report2026-10-29SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-27SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-08SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-07-02424B5SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-05-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-03-268-KCurrent report2026-03-20SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-128-KCurrent report2026-03-11SEC
2026-02-20EFFECTEffectiveness filing by commission orderSEC
2026-02-17CORRESPSEC
2026-02-17UPLOADUpload SubmissionSEC
2026-02-134Statement of changes in beneficial ownership of securities2026-02-12SEC
2026-02-134Statement of changes in beneficial ownership of securities2026-02-12SEC
2026-02-134Statement of changes in beneficial ownership of securities2026-02-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200183.17K9
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC12.57%
BlackRock, Inc.11.16%
Krensavage Asset Management, LLC9.86%
FARALLON CAPITAL MANAGEMENT, L.L.C.8.32%
Deep Track Capital, LP4.97%
ADAR1 Capital Management, LLC4.62%
VANGUARD CAPITAL MANAGEMENT LLC4.17%
Spruce Street Capital LP3.74%
ACADIAN ASSET MANAGEMENT LLC3.50%
VANGUARD PORTFOLIO MANAGEMENT LLC3.48%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.52%
BlackRock Health Sciences Opportunities Portfolio1.69%
Fidelity Small Cap Index Fund1.06%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.97%
iShares Biotechnology ETF0.67%
VANGUARD STRATEGIC EQUITY FUND0.62%
VANGUARD RUSSELL 2000 INDEX FUND0.56%
VANGUARD EXPLORER FUND0.48%

OakChart. ENTA. Cached 15 minutes.